Unknown

Dataset Information

0

Dysfunctional epileptic neuronal circuits and dysmorphic dendritic spines are mitigated by platelet-activating factor receptor antagonism.


ABSTRACT: Temporal lobe epilepsy or limbic epilepsy lacks effective therapies due to a void in understanding the cellular and molecular mechanisms that set in motion aberrant neuronal network formations during the course of limbic epileptogenesis (LE). Here we show in in vivo rodent models of LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and that PAF receptor (PAF-r) ablation mitigates its progression. Synthetic PAF-r antagonists, when administered intraperitoneally in LE, re-establish hippocampal dendritic spine density and prevent formation of dysmorphic dendritic spines. Concomitantly, hippocampal interictal spikes, aberrant oscillations, and neuronal hyper-excitability, evaluated 15-16 weeks after LE using multi-array silicon probe electrodes implanted in the dorsal hippocampus, are reduced in PAF-r antagonist-treated mice. We suggest that over-activation of PAF-r signaling induces aberrant neuronal plasticity in LE and leads to chronic dysfunctional neuronal circuitry that mediates epilepsy.

SUBMITTER: Musto AE 

PROVIDER: S-EPMC4957208 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dysfunctional epileptic neuronal circuits and dysmorphic dendritic spines are mitigated by platelet-activating factor receptor antagonism.

Musto Alberto E AE   Rosencrans Robert F RF   Walker Chelsey P CP   Bhattacharjee Surjyadipta S   Raulji Chittalsinh M CM   Belayev Ludmila L   Fang Zhide Z   Gordon William C WC   Bazan Nicolas G NG  

Scientific reports 20160722


Temporal lobe epilepsy or limbic epilepsy lacks effective therapies due to a void in understanding the cellular and molecular mechanisms that set in motion aberrant neuronal network formations during the course of limbic epileptogenesis (LE). Here we show in in vivo rodent models of LE that the phospholipid mediator platelet-activating factor (PAF) increases in LE and that PAF receptor (PAF-r) ablation mitigates its progression. Synthetic PAF-r antagonists, when administered intraperitoneally in  ...[more]

Similar Datasets

| S-EPMC3518588 | biostudies-literature
| S-EPMC4509985 | biostudies-literature
| S-EPMC11296318 | biostudies-literature
| S-EPMC4070952 | biostudies-literature
| S-EPMC4471661 | biostudies-other
| S-EPMC2800307 | biostudies-literature
| S-EPMC3752161 | biostudies-literature
| S-EPMC5709047 | biostudies-literature
| S-EPMC4286724 | biostudies-literature
| S-EPMC6802951 | biostudies-literature